IKIllia Vasylovych Koshurba

Illia Vasylovych Koshurba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Illia Vasylovych Koshurba has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mechanisms of immune response formation in ischemic cardiac injury: from initial molecular events in damaged cells to the development of a full-scale inflammatory reaction, involvement of regulatory cytokines, and structural remodeling of cardiac tissue

    by М.о. Chyzh, D.V. Vasylyev, Т.і. Liadova, M.S. Matvieienko, F.V. Hladkykh, I.V. Koshurba

    Background. Understanding of current scientific advances in cardiac injury during ischemia/reperfusion, particularly the immunological mechanisms underlying inflammation in this condition, provides the basis for developing potential therapeutic strategies targeting specific components of this process in the treatment of ischemic myocardial damage. Purpose – to systematize and summarize contemporary scientific data on the key immunological mechanisms of inflammation in ischemic heart injury, and to outline pathogenetic pathways that may serve as potential targets for selective anti-inflammatory therapeutic interventions. Materials and Methods. A selection of publications was performed followed by systematic analysis using the databases PubMed (https://pubmed.ncbi.nlm.nih.gov/), Clinical Key Elsevier (https://www.clinicalkey.com), Cochrane Library (https://www.cochranelibrary.com/), eBook Business Collection (https://www.ebsco.com/), and Google Scholar (https://scholar.google.com/). These sources provided information on immunological mechanisms of inflammation in ischemic heart injury, the role of innate and adaptive immune cells, signaling pathways of inflammatory activation, and cytokine cascades. Results. Ischemia/reperfusion injury of the heart unfolds as a programmed sequence of immunopathological reactions. Damage-associated molecular patterns initiate cascades involving cellular and humoral components of both innate and adaptive immunity. Dysregulation of these processes influences the extent of myocardial injury during acute ischemia and reperfusion, particularly in the presence of the «no-reflow» phenomenon, and in subsequent scar formation and myocardial remodeling. Modulation of cellular and molecular mechanisms may represent a promising therapeutic target. Conclusions. Ischemia/reperfusion injury of the myocardium results from a complex sequence of immune events that determine the balance between tissue damage and repair. The combination of targeted immunomodulation with support of resolution mechanisms of inflammation constitutes a promising therapeutic strategy to reduce infarct-related injury and improve myocardial recovery.

  • Open Access

    Cryopreserved cells and tissue extracts in cardioprotection: current state of the problem

    by T.V. Kozlova, М.о. Chyzh, Т.і. Liadova, F.V. Hladkykh, I.V. Koshurba

    Background. Cryopreservation is a key element of modern cell therapy, however, the freezing and thawing procedure can modify the biological properties of mesenchymal stromal cells, affect their secretory profile, and reduce therapeutic efficacy. Extracellular vesicles and cryopreserved tissue extracts are of growing interest, which are considered as cell-free alternatives in cardioprotection. Purpose – the aim of the work is to summarize current data on changes in the biological characteristics of mesenchymal stromal cells after cryopreservation, to analyze their paracrine potential with an emphasis on extracellular vesicles, and to evaluate the therapeutic significance of cryopreserved tissue extracts in cardioprotection in ischemic- reperfusion injury of the myocardium. Materials and Methods. A systematic search was conducted in PubMed, ClinicalKey, Cochrane Library, eBook Business Collection and Google Scholar databases for keywords related to mesenchymal stromal cells, cryopreservation, extracellular vesicles, exosomes and cardioprotection. The selection of articles was carried out according to the criteria of relevance to the topic, evidence and availability of full texts. Results. It has been shown that cryopreservation can reduce the viability of mesenchymal stromal cells, change their phenotype and secretory activity, which affects clinical outcomes. At the same time, extracellular vesicles and cryoextracts demonstrate more stable properties, lower risks and a wide range of cytoprotective effects, including angiogenesis, modulation of inflammation and activation of regenerative processes. Extracellular vesicle from different sources of mesenchymal stromal cells have specific biological properties, which allows us to consider them as promising tools for cell-free cardioprotection. Conclusions. Cryopreservation is a necessary but critical stage of mesenchymal stromal cells preparation that requires standardization. Extracellular vesicle and cryopreserved extracts may become an effective alternative to cell therapy due to their stability, safety, and pronounced cardioprotective properties.

  • Multilevel determinants of ischemic cardiac injury: cellular stress responses, mitochondrial insufficiency, and endothelial dysfunction

    by М.о. Chyzh, F.V. Hladkykh, Т.і. Liadova, A.L. Liashok, M.S. Matvieienko, O.V. Kanishcheva, I.V. Koshurba

    Background. Impaired blood supply to the heart leads to profound metabolic, cellular, and microvascular changes that determine the extent of acute injury and the subsequent development of heart failure. Understanding the coordinated action of energy, ionic, mitochondrial, and inflammatory mechanisms is essential for developing modern approaches to the treatment and prevention of complications after acute cardiac ischemia. Purpose – to systematize and summarize current data on the key cellular, molecular, mitochondrial, microcirculatory, and endothelial mechanisms of ischemic and ischemia- reperfusion myocardial injury. Materials and Methods. A literature search was conducted in international scientific databases containing clinical and experimental data on the pathophysiology of cardiac injury. The first stage used thematic keywords. The second stage selected publications based on abstract analysis. The third stage conducted a full-text study and content analysis of sources that covered the cellular, metabolic, and microvascular mechanisms of acute ischemia. Results. Ischemia causes a rapid restructuring of energy metabolism with the accumulation of incomplete oxidation products, the development of acid-base shifts and a violation of the ionic balance. There is a progressive accumulation of calcium, a decrease in the activity of membrane pumps and a loss of structural integrity of the cell. Mitochondria in conditions of oxygen deficiency and restoration of blood flow become a source of excessive oxygen radicals, which trigger the opening of the permeability pore, energy collapse and cell death. Microcirculation disorders and endothelial dysfunction limit the effectiveness of blood flow restoration. The combination of these mechanisms determines the extent of damage, the rate of recovery and the scale of cardiac remodeling. Conclusions. Ischemic and reperfusion injury is the result of an interaction of metabolic, ionic, mitochondrial, and microvascular changes. Identification of their key nodes creates the basis for the development of new methods of targeted therapy.


  • Ulcerogenicity: strategies for prevention and modern approaches to the treatment of peptic ulcer disease

    by Fedir Volodymyrovych Hladkykh, Illia Vasylovych Koshurba, Tetyana Ivanivna Liadova, Mykola Oleksiiovych Chyzh, Mariia Serhiivna Matvieienko

    Монографія присвячена сучасним аспектам етіології та патогенезу виразкової хвороби шлунка, зокрема розглядається ульцерогенність нестероїдних протизапальних засобів і новітні стратегії профілактики та лікування цієї патології. Окрему увагу приділено механізмам гастропротекції, в тому числі використанню біологічних засобів та модифікації нестероїдних протизапальних засобів для зменшення їх ульцерогенної дії. Детально описано антиульцерогенну активність кріоекстракту плаценти на різних моделях виразкової хвороби шлунка. Розглянуті імунологічні механізми, які супроводжують передракові зміни слизової оболонки шлунка, а також роль інфекції Helicobacter pylori у розвитку цього захворювання. Монографія буде корисною для широкого кола лікарів-клініцистів, зокрема гастроентерологів, імунологів, а також фармакологів, біохіміків, патофізіологів та здобувачів вищої освіти медичного та фармацевтичного профілю. Таблиць – 17, рисунків – 13, бібліографія – 290 посилань. The monograph is dedicated to contemporary aspects of the etiology and pathogenesis of gastric ulcer disease, specifically addressing the ulcerogenicity of non-steroidal anti-inflammatory drugs and the latest strategies for prevention and treatment of this pathology. Special attention is given to the mechanisms of gastroprotection, including the use of biological agents and the modification of non-steroidal anti-inflammatory drugs to reduce their ulcerogenic effects. The anti-ulcerogenic activity of placental cryoextract is described in detail on various models of gastric ulcer disease. Immunological mechanisms associated with precancerous changes in the gastric mucosa are discussed, as well as the role of Helicobacter pylori infection in the development of this disease. The monograph will be valuable to a wide range of clinicians, including gastroenterologists, immunologists, as well as pharmacologists, biochemists, pathophysiologists, and students in medical and pharmaceutical fields. Tables – 17, figures – 13, bibliography – 290 references.

  • Hepatoprotection: innovative strategies and clinical perspectives of biotechnological approaches

    by Illia Vasylovych Koshurba, Fedir Volodymyrovych Hladkykh, Tetyana Ivanivna Liadova, Mykola Oleksiiovych Chyzh

    Монографію присвячено експериментальному обґрунтуванню розробки інноваційного підходу до гепатопротекції та вивченню комплексу механізмів дії безклітинних кріоконсервованих біологічних засобів, зокрема кріоекстракту плаценти, кріоекстракту селезінки та кондиціонованого середовища мезенхімальних стовбурових клітин. Узагальнено результати досліджень гепатопротекторних властивостей безклітинних кріоконсервованих біологічних засобів на моделях тетрахлорметанового, етанол-тетрахлорметанового, Д-галактозамінового, парацетамолового, диклофенакнатрієвого та аутоімунного уражень печінки. Монографія буде корисною для широкого кола лікарів-клініцистів, зокрема гепатологів та гастроентерологів, а також фармакологів, біохіміків, патофізіологів та здобувачів вищої освіти медичного та фармацевтичного профілю. Таблиць – 36, рисунків – 21, бібліографія – 251 посилання. The monograph is dedicated to the experimental justification of the development of an innovative approach to hepatoprotection and the study of the complex mechanisms of action of acellular cryopreserved biological agents, including cryoextracts of placenta, spleen, and conditioned medium of mesenchymal stem cells. The results of studies on the hepatoprotective properties of acellular cryopreserved biological agents are generalized based on models of liver damage caused by carbon tetrachloride, ethanol-carbon tetrachloride, D-galactosamine, paracetamol, diclofenac sodium and autoimmune injury. The monograph will be useful for a wide range of clinical doctors, especially hepatologists and gastroenterologists, as well as pharmacologists, biochemists, pathophysiologists, and students of higher education in the medical and pharmaceutical fields. Tables – 36, figures – 21, bibliography – 251 references.


  • Open Access

    Cell-free biological agents: new horizons in the treatment of premature newborns (literature review)

    by F.V. Hladkykh, I.V. Koshurba, Ukraine Communal Non-Profit Enterprise Chernivtsi Regional Perinatal Center, M.O. Chyzh, P.S. Zhuchenko, Yu.V. Koshurba

    Preterm birth, is a complex syndrome and remains a major global health problem. Taking into account the plasticity and regenerative potential of developing organs, nowadays the most promising therapeutic strategy is the use of mesenchymal stem cells (MSCs) and their derivatives. Aim. To summarize current information about the therapeutic potential of cell-free biological agents in the treatment of diseases of premature newborns according to data from open sources of information. Publications have been selected, which covered information on the use of conditioned media and MSC exosomes in the treatment of diseases of premature newborns. In comparison to MSCs, the use of cell-free agents has advantages: the use of the secretome eliminates the risks potentially associated with the transplantation of living and proliferative cell populations, including immune compatibility, tumorigenicity, emboli formation, and transmission of infections; MSC-derived secretome can be evaluated for safety, dosage, and efficacy in a manner similar to conventional pharmaceutical agents; storage can be carried out without the use of potentially toxic cryopreservatives for a long period without losing the effectiveness of the product; the use of secretome from MSCs, such as conditioned MSC medium, is more economical and more practical for clinical use, as it avoids invasive cell collection procedures; mass production is possible using custom-made cell lines in controlled laboratory conditions, providing a convenient source of bioactive factors; the time and cost of expansion and maintenance cultured stem cells could be greatly reduced, and ready-made secretome therapies could be immediately available for the treatment of acute conditions; a biological product obtained for therapeutic use can be modified to have the desired cell-specific effects. Conclusions. The treatment of premature newborns represents a unique clinical task, since their diseases involve dynamic physiological processes in immature, developing organs. The introduction into clinical use of cell-free biological agents is one of the most promising areas in the development of neonatology and will obviously change the paradigms in the treatment of a number of diseases of newborns, in particular bronchopulmonary dysplasia, hypoxic ischemic encephalopathy and necrotizing enterocolitis. No conflict of interests was declared by the authors.


  • Open Access

    BRONCHOPULMONARY DYSLASIA OF NEWBORNS AND PROSPECTS OF CELL THERAPY IN UKRAINE AND WORLDWIDE

    by Illia V. Koshurba, Fedir V. Hladkykh, Yurii V. Koshurba

    Introduction. Premature birth is a serious challenge for modern medicine – in the world, about 14.9 million babies are born before 37 weeks of pregnancy, which is approximately 11.0% of all newborns. Bronchopulmonary dysplasia (BLD) is the most common form of chronic lung disease that affects premature babies and contributes to their morbidity and mortality. BPD develops in approximately 25.0% of infants with a birth weight of less than 1,500 g. Among infants born at less than 28 weeks' gestational age, the overall incidence of BPD is estimated to be 48–68%. The limited possibilities of BPD pharmacotherapy prompted the search for new therapeutic approaches. One of the alternatives is biological therapy based on mesenchymal stem cells (MSCs), secretome of MSCs, cryopreserved tissue extracts, etc. The aim of the study: to characterize current information on the therapeutic potential of mesenchymal stem cells in the treatment of newborns with bronchopulmonary dysplasia. Materials and methods. Publications were selected based on the databases PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection, and Google Scholar, which covered information about the pathogenesis of BPD and the prospects for the use of MSCs in the treatment of newborns. Results. Over the past decades, the understanding of the pathogenesis of BPD has evolved from a complication of secondary lung damage after mechanical ventilation and the effect of increased oxygen concentration to a multifactorial disease in which prenatal and postnatal factors are involved. Adult stem cells have been found to be naturally capable of sustaining, generating and replacing terminally differentiated cells. Stem cells function in response to physiological cell turnover or tissue damage due to trauma caused by mechanical ventilation, barotrauma, volutrauma, and hyperoxia in preterm infants. It is believed that the therapeutic effect of MSCs is related to their immunomodulatory, anti-inflammatory, angiogenic, antibacterial and regenerative effects. According to ClinicalTrials.gov, out of 301 clinical studies devoted to BPD, 18 clinical studies are currently known to study the effectiveness of MSCs in the treatment of newborns with BPD, which have already involved 770 newborns. The largest number of studies is conducted in East Asian countries (5 in China, 5 in the Republic of Korea, and 2 in Taiwan). Conclusions. Currently, research into the clinical therapy of BPD with stem cells is mainly focused on umbilical cord blood MSCs, umbilical cord MSCs, and bone marrow MSCs. Success in proving the safety and feasibility of incorporating stem cells for BPD led to the appearance of the biological drug PNEUMOSTEM® – a product of allogeneic MSCs obtained from human umbilical cord blood. Вступ. Передчасні пологи є серйозним викликом для сучасної медицини – у світі близько 14,9 мільйонів дітей народжуються до 37 тижнів вагітності, що становить приблизно 11,0% усіх новонароджених. Найпоширенішою формою хронічного захворювання легень, яке вражає недоношених дітей і сприяє їх захворюваності та смертності виступає бронхолегенева дисплазія (БЛД). БЛД розвивається приблизно у 25,0% немовлят з вагою при народженні менше 1500 г. Серед немовлят, які народилися менше 28 тижнів гестаційного віку, загальна захворюваність на БЛД оцінюється в межах 48–68%. Обмежені можливості фармакотерапії БЛД спонукали до пошуку нових терапевтичних підходів. Однією з альтернатив є біологічна терапія на основі мезенхімальних стовбурових клітин (МСК), секретому МСК, кріоконсервованих екстрактів тканин та ін. Ціль дослідження: охарактеризувати сучасні відомості щодо терапевтичного потенціалу мезенхімальних стовбурових клітин у лікуванні новонароджених з бронхолегеневою дисплазією. Матеріали та методи. Підбір публікацій виконано за базами даних PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection, та Google Scholar, у яких висвітлювались відомості про патогенез БЛД та перспективи застосування МСК у лікуванні новонароджених. Результати. За останні десятиліття уявлення про патогенез БЛД еволюціонувало від ускладнення вторинного ураження легень після механічної вентиляції та дії підвищеної концентрації кисню до мультифакторного захворювання, у якому задіяні пренатальні та постнатальні фактори. Було виявлено, що стовбурові клітини дорослої людини природно здатні підтримувати, генерувати та замінювати кінцево-диференційовані клітини. Стовбурові клітини функціонують у відповідь на фізіологічний обмін клітин або пошкодження тканин внаслідок...

  • Open Access

    GENDER DIFFERENCES IN THE EFFECT OF ANTIULCER DRUGS AND PLACENTA CRYOEXTRACT ON THE INTENSITY OF LIPID PEROXIDATION AND THE ACTIVITY OF THE ANTIOXIDANT SYSTEM IN EXPERIMENTAL HEPATITIS WITH ETHANOL-INDUCED CIRRHOSIS

    by Illia V. Koshurba, Fedir V. Hladkykh, Mykola O. Chyzh, Mykhailo M. Marchenko, Yurii V. Koshurba, Volodymyr B. Hrishyn

    Introduction. It is well recognized that drug metabolism products in the liver can induce oxidative stress and mitochondrial dysfunction, leading to the development of hepatocellular injury. As a potential agent capable of counteracting the hepatotoxic effects of drugs, we focused our attention on a domestic biotechnological preparation – cryopreserved placental extract (CPE). The aim. To characterize gender differences in the effect of esomeprazole, clarithromycin, metronidazole (E/C/M), and CPE on the intensity of lipid peroxidation and the activity of the antioxidant system in tetrachloromethane (CCl4) hepatitis with a background of ethanol-induced cirrhosis (ETCM). Materials and methods. The study was conducted with varying levels of sex hormones on 112 male and female rats. Chronic ETCM was induced by administering a 50.0% oil solution of CCl4 at a dose of 8 ml/kg body weight of the animals twice a week, in combination with a 5.0% ethanol solution for drinking over a period of 45 days. The content of TBA-RP in liver homogenates was determined spectrophotometrically by the method described by Asakawa T. et al. Catalase activity in liver homogenates was determined spectrophotometrically according to the method of Korolyuk M.A. and co-authors. Results. The most pronounced increase in lipid peroxidation processes was observed in females with chronic ETCM-induced liver damage and administration of antiulcer drugs following ovariectomy, resulting in a TBA-RS content of 36.1±2.79 μmol/kg of tissue. Administration of E/C/M in animals with chronic liver damage led to a suppression of the antioxidant system, as evidenced by a decrease in catalase activity in liver tissues. Conclusion. The combined use of anti-ulcer drugs and CPE on the background of chronic ETCM mitigated the activation of lipid peroxidation processes, which was indicated by a statistically significant (p < 0.001) 2.7-fold lower content of TBA-RP in liver homogenates. Additionally, it was established that the administration of CPE was accompanied by a statistically significant increase in catalase activity in females, more prominently than in males. In females without changes in hormonal status, the introduction of CPE resulted in a growth (p < 0.001) of catalase activity by 75.0%, with the most significant increase observed in females after ovariectomy – catalase activity statistically significantly (p < 0.001) increased by 2.6 times compared to the indicators of females not administered with CPE. The administration of CPE in female rats without altering hormonal status was accompanied by a twofold (p < 0.01) increase in the antioxidant-prooxidant index compared to male rats, indicating more pronounced antioxidant properties of CPE in female rats.

  • Open Access

    Modern hepatoprotection: a narrative review of existing approaches and prospects for the use of biotechnological drugs

    by F. V. Hladkykh, I. V. Bielochkina, I. V. Koshurba, M. O. Chyzh

    The prevalence of acute and chronic liver diseases is increasing worldwide, which affects the quality of life and can lead to dangerous, life-threatening complications. Almost 50.0 % of all cases of acute liver failure are caused by drugs, and the overall mortality due to drug-induced liver injury reaches 5.0–11.9 %. In 2020, the hospital incidence of diseases of the digestive organs in Ukraine amounted to 430,593 cases among the adult population, of which 11,976 were fatal. The aim of the study: to characterize modern approaches to hepatoprotection and prospects of biological therapy based on data from open sources of information. Materials and methods. Publications were selected based on the PubMed, ClinicalKey Elsevier, Cochrane Library, eBook Business Collection, and Google Scholar databases, which covered information about modern approaches to the treatment of liver diseases. Results. Patients with chronic liver disease are at risk of extrahepatic complications related to liver cirrhosis and portal hypertension, as well as organ-specific complications of certain liver diseases. These complications can impair the quality of life and increase morbidity and mortality before and after liver transplantation. With chronic damage to the liver by toxic substances, the development of fatty dystrophy against the background of connective tissue changes in the form of nonspecific reactive hepatitis is more often observed. Hepatoprotectors are a pharmacotherapeutic group of heterogeneous drugs that prevent the destruction of cell membranes and stimulate the regeneration of hepatocytes. According to the Anatomical Therapeutic and Chemical classification of drugs (ATC classification), hepatoprotectors take their place in the group of drugs affecting the digestive system and metabolism (A), intended for the treatment of diseases of the liver and biliary tract (A05). One of the promising directions of biological therapy in patients with liver pathology is the use of means obtained from the fetoplacental complex. Conclusions. Cell therapy in clinically significant volumes is an actual area of modern hepatology. The most promising directions of biological therapy in clinical hepatology are the use of mesenchymal stem cells, agents obtained from the fetoplacental complex, and gene therapy.


  • Open Access

    Low-dose radiation therapy for COVID-19

    by F.V. Hladkykh, I.V. Koshurba, Н.V. Kulinich

    Background. Radiation therapy is one of the most effective treatments in patients with malignant neoplasms, it also plays an important role in the treatment of non-oncological di­seases. The coronavirus disease 2019 (COVID-19) pandemic has prompted a review of the long-forgotten idea of using low-dose radiation therapy (LDRT) in patients with lobar and interstitial pneumonia. Historically, from 1905 to the mid-1940s, LDRT was used to treat pneumonia, and evidence suggests that it might improve survival and provide rapid relief of respiratory symptoms. The purpose was to summarize current information about ­using low-dose radiation therapy in the treatment of patients with ­COVID-19. Materials and methods. A selection of publications was carried out, which covered information on the possibilities of using low-dose radiation therapy in the treatment of patients with COVID-19. At the first stage, a search was conducted for lite­rary sources using the keywords: COVID-19, low-dose radiation therapy. At the second stage, summaries of articles were studied and publications that did not meet the research criteria were excluded. At the third stage, the full texts of the selected articles were studied for compliance with the criteria for inclusion in the reference list and research relevance. Results. As of August 1, 2023, according to ClinicalTrials.gov, among 9,244 clinical trials associated with COVID-19, sixteen are currently being conduc­ted. They examine the effectiveness of LDRT in the treatment of patients with COVID-19 and already involve 1,038 patients. The largest number of studies is conducted in European countries. It has been shown that LDRT selectively attenuates oxidative stress to an inflammatory stimulus and inhibits the nitric oxide production pathway. This may contribute to its anti-inflammatory and vascular effects. At the same time, heme oxygenase 1 and other antioxidants are induced, they are mediated by Nrf2, which is the main regulator of endogenous antioxidant, anti-stress, analgesic reactions, and is also closely related to nicotinamide adenine dinucleotide phosphate and the metabolic pathway of pentose phosphate. Nrf2 may be critical for pain relief associated with edema formation and possibly plays a major role in the effects of LDRT, whereas direct functional effects of low-dose radiation on the autonomic nervous system and nociception are likely to be smaller. Conclusions. From 1905 to 1946, researchers published the results of more than 15 clinical studies on the effectiveness of radiotherapy for inflammatory lung diseases, which included more than 850 patients and demonstrated the high therapeutic effectiveness of radiation therapy in the indicated pathology. Today, there are 16 ongoing clinical trials in the world devoted to the study of LDRT effectiveness in the treatment of patients with COVID-19, in which 1,038 patients have already been involved. The risk of radiation-induced lung and breast cancer in a 25-year-old woman exposed to 1 Gy whole chest radiation may be as high as 5.9 and 5.5 %, respectively.